SHIFT AI Newsroom · GLOBAL
Tirzepatide Non-Response and Subsequent Semaglutide Response in Class 2 Obesity
Research indicates some individuals with class 2 obesity may not respond to tirzepatide but could respond to semaglutide.
Introduction to Tirzepatide and Semaglutide in Class 2 Obesity
Tirzepatide and semaglutide are medications that have been studied in the context of obesity. Recent research published on Europe PMC discusses the phenomenon of non-response to tirzepatide with subsequent response to semaglutide in individuals with class 2 obesity.
What Does the Evidence Say?
The evidence suggests that for some patients with class 2 obesity, tirzepatide may not be effective, but these patients may respond to semaglutide. This information could be crucial for guiding treatment decisions in clinical practice.
What this means in the UK
This information is relevant to UK healthcare as it may inform treatment decisions for obesity, a significant public health concern.
Known facts
- Tirzepatide non-response with subsequent semaglutide response in class 2 obesity has been observed.